Position in EXEL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$133,559
+$45,637 QoQ
Shares Held
3,114
+55.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Signature Equity Partners, LLC holds $547,942 across 26 Biotechnology names. EXEL ranks #3 (24.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
347 | $154,949 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
751 | $141,976 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
3,114 | $133,559 | |
| 4 | ACAD |
Acadia Pharmaceuticals Inc
|
1,907 | $42,449 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
600 | $24,186 | |
| 6 | RPRX |
Royalty Pharma plc
|
231 | $11,081 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
120 | $7,755 | |
| 8 | INSM |
INSMED Inc
|
43 | $7,031 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $133,559 | 3,114 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $87,922 | 2,006 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||